Gaithersburg, MD, United States
Gaithersburg, MD, United States

Time filter

Source Type

Patent
Sequoia Pharmaceuticals Inc. | Date: 2016-01-11

Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.


Patent
Sequoia Pharmaceuticals Inc. | Date: 2015-02-09

Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.


Patent
Sequoia Pharmaceuticals Inc. | Date: 2014-07-29

Methods of inhibiting cytochrome P450 2D6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450 2D6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 2D6 enzymes.


Patent
Sequoia Pharmaceuticals Inc. | Date: 2010-05-24

Inhibitors of the hepatitis C virus (HCV) NS3 protease are provided. In particular, bimacrocyclic compounds and their pharmaceutical compositions for the treatment of HCV infections are provided. Methods of making the bimacrocyclic compounds and their pharmaceutical compositions, and methods of using the compounds for treating HCV infections are also provided.


Patent
Sequoia Pharmaceuticals Inc. | Date: 2011-07-19

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.


Patent
Sequoia Pharmaceuticals Inc | Date: 2014-12-09

Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.


Patent
Sequoia Pharmaceuticals Inc. | Date: 2011-11-01

Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.


Patent
Sequoia Pharmaceuticals Inc. | Date: 2012-02-29

Resistance-repellent and multi-drug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.


Patent
Sequoia Pharmaceuticals Inc. | Date: 2012-02-29

Resistance-repellent and multi-drug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.


Patent
Sequoia Pharmaceuticals Inc. | Date: 2013-07-09

Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.

Loading Sequoia Pharmaceuticals Inc. collaborators
Loading Sequoia Pharmaceuticals Inc. collaborators